Drug
Humanized 3f8 Bispecific Antibody
Humanized 3f8 Bispecific Antibody: highest development phase Phase 1/2, developed by Y-mAbs Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Y-mAbs Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Humanized 3F8 Bispecific Antibody NCT03860207 | Phase 1/2 | Neuroblastoma |
Latest
No recent events.
Follow Humanized 3f8 Bispecific Antibody on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.